Amylin Pharmaceuticals, Inc. Commits $1.5 Million to American Diabetes Association Distinguished Clinical Scientist Award
2007 JUL 9 -- The American Diabetes Association (ADA) Research Foundation announced a $1.5 million commitment by Amylin Pharmaceuticals, Inc. to support its Distinguished Clinical Scientist Award (DCSA) -- the ADA's most prestigious research award aimed specifically at clinical programs. The award is the largest annual award given by the ADA and recognizes outstanding scientists who have advanced the field of patient-oriented diabetes research. "Exploring cutting-edge research that can be translated into the realm of patient care is crucial to advancing our understanding of current and potential treatments or a possible cure for diabetes," said Don Wagner, chair, ADA Research Foundation. "We are grateful to Amylin Pharmaceuticals for their commitment to diabetes and to this important program that will further the ADA's mission." Clinical research -- research that utilizes the knowledge gained in the lab and provides improved care for diabetes patients -- is of critical importance to the future of diabetes research. The ADA provides several types of awards to support investigators in this area, the most prominent being the Distinguished Clinical Scientist Award. This award currently provides flexible funding for five established full-time researchers that have been selected by ADA's peer-reviewed panel and are expected to be at the forefront in leading areas of clinical research in the years ahead. Amylin will support the DCSA through 3 years of funding at $500,000 each year as part of their sponsorship commitment. "Translating basic science into beneficial clinical outcomes is critical. This enables people with diabetes to live longer and healthier lives," said Daniel Bradbury, President and Chief Executive Officer, Amylin Pharmaceuticals, Inc. "We are pleased to collaborate with the ADA to enable the advancement of science towards this common goal." Diabetes is one of this nation's most prevalent, debilitating, deadly and costly diseases, affecting nearly 21 million children and adults in the United States. One in three Americans -- and one in two minorities -- born in 2000 will develop diabetes in their lifetime, according to the Centers for Disease Control and Prevention. The cost of diabetes in America in 2002 was more than $132 billion. Keywords: Amylin Pharmaceuticals Inc., Diabetes, Pharmaceutical Business, Pharmaceutical Company, American Diabetes Association. This article was prepared by Diabetes Week editors from staff and other reports. Copyright 2007, Diabetes Week via NewsRx.com.
|
